Opiate Substitution Treatment
"Opiate Substitution Treatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.
| Descriptor ID |
D058850
|
| MeSH Number(s) |
E02.319.620
|
| Concept/Terms |
Opiate Substitution Treatment- Opiate Substitution Treatment
- Opiate Substitution Treatments
- Substitution Treatment, Opiate
- Substitution Treatments, Opiate
- Treatment, Opiate Substitution
- Treatments, Opiate Substitution
- Opioid Substitution Treatment
- Opioid Substitution Treatments
- Substitution Treatment, Opioid
- Substitution Treatments, Opioid
- Treatment, Opioid Substitution
- Treatments, Opioid Substitution
- Opioid Substitution Therapy
- Opioid Substitution Therapies
- Substitution Therapies, Opioid
- Substitution Therapy, Opioid
- Therapies, Opioid Substitution
- Therapy, Opioid Substitution
- Opiate Replacement Therapy
- Opiate Replacement Therapies
- Replacement Therapies, Opiate
- Replacement Therapy, Opiate
- Therapies, Opiate Replacement
- Therapy, Opiate Replacement
- Opioid Replacement Therapy
- Opioid Replacement Therapies
- Replacement Therapies, Opioid
- Replacement Therapy, Opioid
- Therapies, Opioid Replacement
- Therapy, Opioid Replacement
|
Below are MeSH descriptors whose meaning is more general than "Opiate Substitution Treatment".
Below are MeSH descriptors whose meaning is more specific than "Opiate Substitution Treatment".
This graph shows the total number of publications written about "Opiate Substitution Treatment" by people in this website by year, and whether "Opiate Substitution Treatment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 0 | 2 |
| 2025 | 5 | 0 | 5 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Opiate Substitution Treatment" by people in Profiles.
-
An Examination of Buprenorphine and Norbuprenorphine Concentrations in Inpatients Receiving Medications for Opioid Use Disorder. J Appl Lab Med. 2026 Jul 01; 11(4):735-747.
-
Addiction care outcomes between insured and state opioid response grant-funded patients in a Medicaid non-expansion state. J Subst Use Addict Treat. 2026 Jun; 185:209901.
-
Training in medications for opioid use disorder and buprenorphine prescribing in the post X-waiver era: Insights from a nationwide, multispecialty survey. Prev Med. 2026 02; 203:108485.
-
Gaps in buprenorphine access: Examining provider availability and treatment continuity. J Subst Use Addict Treat. 2026 Jan; 180:209818.
-
Telehealth Buprenorphine Initiation for Opioid Use Disorder Among American Indian and Alaska Native Veterans, April 2017-March 2023. Telemed J E Health. 2025 Nov; 31(11):1333-1341.
-
Association between buprenorphine adherence for opioid use disorder and clinical events and healthcare spending among older patients. J Subst Use Addict Treat. 2025 Sep; 176:209740.
-
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.
-
Comparative effectiveness of buprenorphine adherence with telemedicine vs. in-person for rural and urban patients. J Am Pharm Assoc (2003). 2025 Mar-Apr; 65(2):102318.
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 12 20; 21(1):220.
-
We Need to Talk About Methadone: Adding Discussions With Patients to Our Care Pathways. Anesth Analg. 2024 01 01; 138(1):e3-e4.